Chemotherapy Effect Clinical Trial
— RETICULA-NPCOfficial title:
Postponing or Omitting Re-irradiation After Tislelizumab Plus Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
This is an open-label, multi-center, phase II trial to evaluate the safety and efficacy of postponing or omitting re-irradiation after systemic therapy with tislelizumab and chemotherapy in patients with unresectable recurrent loco-regionally advanced nasopharyngeal carcinoma. Patients who did not respond to or progressed on another ICI are allowed to receive tislelizumab rechallenge as a subgroup.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | June 30, 2024 |
Est. primary completion date | October 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 90 Years |
Eligibility | Inclusion Criteria: 1. Diagnosed as local recurrence ± regional recurrence after =1 year of radical treatment; 2. Not suitable for surgery; 3. Clinical stage rT3-4N0-2 (rII-IVa, AJCC/UICC 8th);or residual disease afer surgery. 4. ECOG score 0-1; 5. No prior treatment to rNPC, such as radiotherapy, chemotherapy, immunotherapy or biotherapy; 6. No contraindications to immunotherapy or chemoradiotherapy; 7. Adequate marrow function: WBC count = 3×10E9/L, NE count = 1.5×10E9/L, HGB = 90g/L, PLT count = 100×10E9/L; 8. Adequate liver function: ALT/AST = 2.5×ULN, TBIL = 2.0×ULN; 9. Adequate renal function: BUN/CRE = 1.5×ULN or endogenous creatinine clearance = 60ml/min (Cockcroft-Gault formula); 10. Take effective contraceptions during and two months after treatment; 11. Patients must be informed of the investigational nature of this study and give written informed consent. Exclusion Criteria: 1. Have local necrosis in recurrent lesions, estimated with bleeding risk; 2. Unexplained fever > 38.5 ?, except for tumor fever; 3. Treated with = 5 days antibiotics one month before enrollment; 4. Have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy); 5. Have a known history of human immunodeficiency virus (HIV), active Hepatitis B (HBV-DNA =10E3copiers/ml) or hepatitis C virus (HCV) antibody positive; 6. Have =G3 late toxicities, except for skin, subcutaneous tissue or mucosa; 7. Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment; 8. Have known allergy to large molecule protein products or any compound of study therapy; 9. Pregnant or breastfeeding; 10. Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma; 11. Any other condition, including mental illness or domestic/social factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results. |
Country | Name | City | State |
---|---|---|---|
China | Eye and ENT Hospital of Fudan University | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Fudan University |
China,
Kong F, Zhou J, Du C, He X, Kong L, Hu C, Ying H. Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. BMC Cancer. 2018 Nov 20;18(1):1139. doi: 10.1186/s12885-018-5055-5. — View Citation
Liu LT, Chen QY, Tang LQ, Zhang L, Guo SS, Guo L, Mo HY, Zhao C, Guo X, Chen MY, Qian CN, Zeng MS, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ. With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case-control study. BMC Cancer. 2016 Oct 7;16(1):774. — View Citation
Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, Peng J, Xu M, Chen D, Lu X, Wang R, Cao X, Chen X, Lin Z, Xiong J, Lin Q, Xie C, Li Z, Pan J, Li J, Wu S, Lian Y, Yang Q, Zhao C. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016 Oct 15;388(10054):1883-1892. doi: 10.1016/S0140-6736(16)31388-5. Epub 2016 Aug 23. Erratum in: Lancet. 2016 Oct 15;388(10054):1882. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate (ORR) | Defined as either a confirmed CR or a PR, as determined by the investigator using RECIST v1.1Response Evaluation Criteria in Solid Tumors (RECIST) . | 3 months | |
Primary | Progress-free survival (PFS) | Defined from date of enrollment to date of first documentation of progression or death due to any cause. | 2 year | |
Secondary | Overall survival (OS) | Defined from date of enrollment to date of first documentation of death from Defined from date of randomization to date of first documentation of death from any cause or censored at the date of the last follow-up. | 2 year | |
Secondary | Adverse events (AEs) | Analysis of adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. AEs are evaluated by investigators according to the Common Terminology Criteria for Adverse Events, version 5.0 | 2 year | |
Secondary | Quality of life (QoL) | QoL scores were assessed by using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30). | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06376604 -
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
|
N/A | |
Completed |
NCT03753542 -
Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy
|
N/A | |
Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
Completed |
NCT04207359 -
Effects of Creatine Supplementation in Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
Completed |
NCT04173195 -
Comfort Talk (CT) During Outpatient Chemotherapy
|
N/A | |
Recruiting |
NCT06041477 -
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
|
Phase 3 | |
Recruiting |
NCT05014399 -
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
|
||
Recruiting |
NCT03275194 -
HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy
|
Phase 2 | |
Recruiting |
NCT04808466 -
Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Completed |
NCT05131490 -
Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients
|
N/A | |
Completed |
NCT04118322 -
The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy
|
N/A | |
Recruiting |
NCT06043999 -
Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients
|
N/A | |
Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04845490 -
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT04989985 -
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05992337 -
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
|
||
Recruiting |
NCT05424692 -
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
|
N/A | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A |